vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $950.5M, roughly 1.2× Astrana Health, Inc.). Astrana Health, Inc. runs the higher net margin — 0.7% vs -127.8%, a 128.5% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 1.3%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
ASTH vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $1.1B |
| Net Profit | $6.6M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | 1.9% | -116.0% |
| Net Margin | 0.7% | -127.8% |
| Revenue YoY | 42.9% | -2.5% |
| Net Profit YoY | 184.4% | -3093.9% |
| EPS (diluted) | $0.12 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $950.5M | $1.1B | ||
| Q3 25 | $956.0M | $1.0B | ||
| Q2 25 | $654.8M | $1.1B | ||
| Q1 25 | $620.4M | $1.0B | ||
| Q4 24 | $665.2M | $1.1B | ||
| Q3 24 | $478.7M | $1.1B | ||
| Q2 24 | $486.3M | $1.1B | ||
| Q1 24 | $404.4M | $1.1B |
| Q4 25 | $6.6M | $-1.4B | ||
| Q3 25 | $373.0K | $7.5M | ||
| Q2 25 | $9.4M | $-8.4M | ||
| Q1 25 | $6.7M | $-6.4M | ||
| Q4 24 | $-7.8M | $-44.4M | ||
| Q3 24 | $16.1M | $-21.0M | ||
| Q2 24 | $19.2M | $-108.4M | ||
| Q1 24 | $14.8M | $2.0M |
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
| Q4 25 | 1.9% | -116.0% | ||
| Q3 25 | 2.0% | 7.0% | ||
| Q2 25 | 3.1% | 4.3% | ||
| Q1 25 | 3.3% | 4.5% | ||
| Q4 24 | 0.1% | 10.0% | ||
| Q3 24 | 5.9% | 7.4% | ||
| Q2 24 | 6.2% | -2.5% | ||
| Q1 24 | 7.5% | -5.1% |
| Q4 25 | 0.7% | -127.8% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 1.4% | -0.8% | ||
| Q1 25 | 1.1% | -0.6% | ||
| Q4 24 | -1.2% | -3.9% | ||
| Q3 24 | 3.4% | -1.9% | ||
| Q2 24 | 3.9% | -10.2% | ||
| Q1 24 | 3.7% | 0.2% |
| Q4 25 | $0.12 | $-10.23 | ||
| Q3 25 | $0.01 | $0.05 | ||
| Q2 25 | $0.19 | $-0.06 | ||
| Q1 25 | $0.14 | $-0.05 | ||
| Q4 24 | $-0.14 | $-0.32 | ||
| Q3 24 | $0.33 | $-0.15 | ||
| Q2 24 | $0.40 | $-0.79 | ||
| Q1 24 | $0.31 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $779.3M | $2.9B |
| Total Assets | $2.2B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $429.5M | — | ||
| Q3 25 | $463.4M | $432.1M | ||
| Q2 25 | $342.1M | $454.2M | ||
| Q1 25 | $260.9M | $409.9M | ||
| Q4 24 | $290.8M | $558.8M | ||
| Q3 24 | $350.3M | $1.5B | ||
| Q2 24 | $327.7M | $542.8M | ||
| Q1 24 | $337.3M | $658.5M |
| Q4 25 | $779.3M | $2.9B | ||
| Q3 25 | $775.5M | $4.4B | ||
| Q2 25 | $765.5M | $4.5B | ||
| Q1 25 | $745.4M | $4.4B | ||
| Q4 24 | $712.7M | $4.3B | ||
| Q3 24 | $704.6M | $4.6B | ||
| Q2 24 | $678.9M | $4.5B | ||
| Q1 24 | $653.5M | $4.7B |
| Q4 25 | $2.2B | $8.5B | ||
| Q3 25 | $2.2B | $10.1B | ||
| Q2 25 | $1.4B | $10.1B | ||
| Q1 25 | $1.3B | $9.8B | ||
| Q4 24 | $1.4B | $9.6B | ||
| Q3 24 | $1.3B | $11.2B | ||
| Q2 24 | $1.3B | $10.4B | ||
| Q1 24 | $1.2B | $10.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $175.4M |
| Free Cash FlowOCF − Capex | $-6.0M | $148.6M |
| FCF MarginFCF / Revenue | -0.6% | 13.4% |
| Capex IntensityCapex / Revenue | 0.3% | 2.4% |
| Cash ConversionOCF / Net Profit | -0.44× | — |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $175.4M | ||
| Q3 25 | $10.0M | $51.7M | ||
| Q2 25 | $90.9M | $75.9M | ||
| Q1 25 | $16.6M | $-64.5M | ||
| Q4 24 | $-10.9M | $312.6M | ||
| Q3 24 | $34.0M | $42.2M | ||
| Q2 24 | $23.2M | $9.5M | ||
| Q1 24 | $6.0M | $-1.4M |
| Q4 25 | $-6.0M | $148.6M | ||
| Q3 25 | $7.4M | $29.8M | ||
| Q2 25 | $89.5M | $56.7M | ||
| Q1 25 | $13.6M | $-90.0M | ||
| Q4 24 | $-13.5M | $274.9M | ||
| Q3 24 | $31.7M | $15.1M | ||
| Q2 24 | $20.4M | $-18.9M | ||
| Q1 24 | $5.6M | $-26.5M |
| Q4 25 | -0.6% | 13.4% | ||
| Q3 25 | 0.8% | 2.9% | ||
| Q2 25 | 13.7% | 5.4% | ||
| Q1 25 | 2.2% | -8.6% | ||
| Q4 24 | -2.0% | 24.2% | ||
| Q3 24 | 6.6% | 1.4% | ||
| Q2 24 | 4.2% | -1.8% | ||
| Q1 24 | 1.4% | -2.4% |
| Q4 25 | 0.3% | 2.4% | ||
| Q3 25 | 0.3% | 2.1% | ||
| Q2 25 | 0.2% | 1.8% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 0.4% | 3.3% | ||
| Q3 24 | 0.5% | 2.5% | ||
| Q2 24 | 0.6% | 2.7% | ||
| Q1 24 | 0.1% | 2.3% |
| Q4 25 | -0.44× | — | ||
| Q3 25 | 26.69× | 6.89× | ||
| Q2 25 | 9.65× | — | ||
| Q1 25 | 2.48× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 0.40× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
